Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.44 |
| ▸ | SPPL2A | Q8TCT8 | 13/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.36 |
| ▸ | GOT1 | P17174 | 1/20 | 0.36 |
| ▸ | KYAT1 | Q16773 | 1/20 | 0.36 |
| ▸ | KYAT3 | Q6YP21 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25408832 | 1.00 | ANPEP (0.44) | ANPEPSPPL2AHTR2AAADATGOT1 | |
| SCHEMBL26855727 | 0.78 | SPPL2A (0.53) | SPPL2A | |
| SCHEMBL25436458 | 0.77 | SPPL2A (0.40) | SPPL2A | |
| SCHEMBL25410662 | 0.77 | SPPL2A (0.42) | SPPL2AAADAT | |
| SCHEMBL25407200 | 0.77 | SPPL2A (0.42) | SPPL2AAADAT | |
| SCHEMBL31676052 | 0.77 | AADAT (0.44) | SPPL2AHTR2AAADAT | |
| SCHEMBL31675930 | 0.76 | SPPL2A (0.42) | SPPL2A | |
| SCHEMBL26847798 | 0.75 | ANPEP (0.41) | ANPEPHTR2AAADATGOT1KYAT1 | |
| SCHEMBL25407760 | 0.75 | ANPEP (0.41) | ANPEPHTR2AAADATGOT1KYAT1 | |
| SCHEMBL25407546 | 0.75 | SPPL2A (0.60) | SPPL2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263416-A1 | SPPL2a INHIBITORS | INCYTE CORPORATION | 2025-08-21 | — | — | US | disclosed |
| EP-4578451-A2 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | Novartis AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| EP-4214210-B1 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | NOVARTIS AG (CH) | 2025-04-09 | — | — | EP | disclosed |
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| CN-116615425-A | Compounds and compositions as Sppl2a inhibitors | 诺华股份有限公司 | 2023-08-18 | — | — | CN | disclosed |
| EP-4214210-A1 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | Novartis AG (CH) | 2023-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | SPPL2A, SPPL2B, BACE1 | ANPEP 111/4885SPPL2A 1/4885HTR2A 1192/4885 |
| US-20250263416-A1 | SPPL2a INHIBITORS | SPPL2A, SPPL2B, BACE1 | ANPEP 84/4885SPPL2A 1/4885HTR2A 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.